Market News & Trends
Amgen Signs $50-Million Deal to Develop Five Biotech Drugs
Amgen and AstraZeneca recentlyannounced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio: AMG 139, AMG 157, AMG 181,…
Astex Announces Interim Phase I/II AML Data
Astex Pharmaceuticals, Inc. recently announced that interim Phase I/II clinical data from subcutaneous SGI-110, a novel hypomethylating agent, demonstrated differentiated PK profile, good tolerability, and…
Catalent & BASF Join Forces to Solve Bioavailabilty Challenges
Catalent Pharma Solutions and BASF recently announced they have entered into a broad collaboration and Open Alliance to provide solutions to overcome bioavailability challenges of…
GlaxoSmithKline to Increase Its Ownership in Theravance
GlaxoSmithKline plc (GSK) and Theravance, Inc. recently announced they have entered into a stock purchase agreement, under which Theravance will issue, and GSK will acquire,…
OvaScience Raises $37 Million in Series B Financing
OvaScience recently announced it has completed a $37-million Series B financing. The financing was led by General Catalyst. Existing investors, Bessemer Venture Partners and Longwood…
Spectrum Pharmaceuticals to Acquire Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics, Inc. recently announced they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of…
Optimer Pharmaceuticals & Astellas Pharma Strike Deal Worth Up to $110 Million
Optimer Pharmaceuticals, Inc. and Tokyo-based Astellas Pharma Inc. recently announced the execution of an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets…
PharmaForm Announces Manufacturing Agreement
PharmaForm recently announced that Corcept Therapeutics Inc. has chosen them as their primary commercial manufacturer for their newly approved drug product, Korlym. The US FDA…
Sunesis Pharmaceuticals & Royalty Pharma Announce $25-Million Royalty Agreement
Sunesis Pharmaceuticals and Royalty Pharma recently announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development…
4/3/2012
Aptar Pharma's Device Delivers INSYS Therapeutics' Drug Aptar Pharma recently announced INSYS Therapeutics' SUBSYS, which uses an Aptar Pharma Sublingual Unit-Dose Spray (UDS) device, has…
Allena Pharmaceuticals Licenses Worldwide Rights to Hyperoxaluria Portfolio
Allena Pharmaceuticals, Inc. and Althea Technologies recently announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio,…
Aptar Pharma's Device Delivers INSYS Therapeutics' Drug
Aptar Pharma recently announced INSYS Therapeutics' SUBSYS, which uses an Aptar Pharma Sublingual Unit-Dose Spray (UDS) device, has been launched in the US for breakthrough…
Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Adjuvant
Vical Incorporated recently announced researchers at Ehime University in Japan and their collaborators have developed a Vaxfectin-formulated DNA vaccine candidate with the potential to prevent…
3/27/2012
Marinomed's Nasal Spray Achieves Positive Clinical Results Marinomed Biotechnologie GmbH, recently announced that data from a clinical trial for the company's iota-carrageenan nasal spray was…
Bend Research Launches New Biotherapeutics Development Initiative
Bend Research Inc. recently announced an initiative to expand its scientific and engineering expertise into biotherapeutics, including offering new technologies and equipment proven to improve…
Bioniche Life Sciences Secures $20 Million
Bioniche Life Sciences Inc. recently announced it has accepted an offer of a $20 million financing from investment funds managed by US-based Capital Royalty L.P.…
FDA Clears Expanded Compatibility for Ikaria's Delivery Systems
Ikaria, Inc., recently announced that the Center for Devices and Radiological Health (CDRH) branch of the US FDA has granted 510(k) clearance for compatibility of…
Marinomed's Nasal Spray Achieves Positive Clinical Results
Marinomed Biotechnologie GmbH, recently announced that data from a clinical trial for the company's iota-carrageenan nasal spray was presented at the 14th International Symposium on…
Nektar Therapeutics Moving 30 Research Jobs
Nektar Therapeutics recently announced it is consolidating its US-based research scientists at the company's existing San Francisco state-of-the-art R&D center, which is located adjacent to…
Particle Sciences & Pernix Therapeutics Enter Development Agreement
Particle Sciences, Inc. recently announced it is developing with Pernix Therapeutics a new topical dermatology product for the pediatric market. "There are multiple treatments for…
